ClinicalTrials.gg
TerminatedNCT05229601Updated Oct 22, 2025

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

A Phase 1 interventional study of HFB301001 in Soft Tissue Sarcoma, Renal Cell Carcinoma and Uterine Carcinosarcoma, sponsored by HiFiBiO Therapeutics. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by HiFiBiO Therapeutics · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The decision to discontinue the trial was made as part of a strategic review of the Sponsor's global development portfolio. It is not related to any safety concerns, efficacy findings, recruitment difficulties, or issues with trial conduct.

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
423rd of 800
31 · median 35
Started
2022
with 34 others
Phase 1
281 of 958
36 open now
Registered
799th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 423rd largest by enrollment of the 800 interventional ones that give a count, is one of 35 that started in 2022, is one of 281 in phase 1, and was the 799th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer they have.

Read the detailed description

This is a Phase I, first-in-human, open-label, dose escalation and expansion study in adult patients with advanced cancers. The study will comprise of:

  1. A Screening Period of up to 28 days
  2. A Treatment Period during which participants will receive the study drug on the first day of each cycle where each cycle is 28 days. Number of cycles depends on how the disease responds to the study drug
  3. A Follow-Up Period which involves 1 visit
03

Conditions studied

  • Soft Tissue Sarcoma
  • Renal Cell Carcinoma
  • Uterine Carcinosarcoma
  • Hepatocellular Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously received the following for the advanced/ disease:

    • Soft tissue sarcoma: at least 1 line of therapy
    • Renal cell carcinoma: at least 2 lines of therapy;
    • Uterine carcinosarcoma: at least 1 line of therapy;
    • Hepatocellular carcinoma: at least 1 line of therapy
    • Head and neck squamous cell carcinoma: at least 2 lines of therapy
    • Melanoma:

      • BRAF V600E mutant: must have received at least 2 lines of therapy
      • BRAF V600E wild type: must have received at least 1 line of therapy
  • Suitable site to at pre-treatment and on-treatment
  • as determined by (RECIST) 1.1 and immune-RECIST ()
  • performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer therapy within 2 weeks prior to start of study drug.
  • For soft tissue sarcoma only: prior immune therapy or immune agonist antibodies
  • For uterine carcinosarcoma patients only: prior immune therapy
  • Therapeutic radiation therapy within the past 2 weeks
  • Prior exposure to agents targeting the OX40 receptor;
  • Active disease requiring systemic treatment in the previous 2 years;
  • Systemic therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy.
  • Persisting toxicity of >Grade 1 relating to prior anti cancer therapy with the following exceptions:

    • All grades of alopecia are acceptable;
    • Endocrine dysfunction on replacement therapy is acceptable.
  • Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition;
  • Major surgery within 2 weeks of the first dose of study drug;
  • History or presence of drug or non-drug induced interstitial lung disease or pneumonitis ≥Grade 2;
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any of HFB301001;
  • Known active , with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    HFB301001

    Participants will receive HFB301001 via intravenous infusions

    Drug: HFB301001

Interventions

  • DrugHFB301001

    Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively. Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), changes in laboratory values, vital signs and ECG parameters, and tolerability (dose interruptions, reductions, and dose intensity)

    Time frame: Cycle 1 Day 1 to 30 days after the last dose of HFB301001 (each cycle is 28 days)

  2. To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion

    Time frame: Cycle 1 Day 1 to 30 days after the last dose of HFB301001 (each cycle is 28 days)

Secondary outcomes

  1. Objective Response Rate (ORR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 and immune-RECIST (iRECIST)

    Time frame: Baseline to 30 days after the last dose of HFB301001 (each cycle is 28 days), assessed up to 3 years

  2. Disease Control Rate (DCR) as determined by RECIST1.1 and iRECIST

    Time frame: Baseline to 30 days after the last dose of HFB301001 (each cycle is 28 days), assessed up to 3 years

  3. Duration of Response (DOR) as determined by RECIST1.1 and iRECIST

    Time frame: Start of first response to first date of disease progression, clinical progression or death, whichever occurs first, assessed up to 3 years

  4. Progression Free Survival (PFS) as determined by RECIST1.1 and iRECIST

    Time frame: Baseline to disease progression or death, whichever occurs first, assessed up to 3 years

  5. Minimum serum concentration (Cmin)

    Time frame: Cycle 1 Day 1 to day of the last dose of HFB301001 (each cycle is 28 days)

  6. Maximum serum concentration (Cmax)

    Time frame: Cycle 1 Day 1 to day of the last dose of HFB301001 (each cycle is 28 days)

  7. Area under the concentration versus time curve (AUC)

    Time frame: Cycle 1 Day 1 to day of the last dose of HFB301001 (each cycle is 28 days)

  8. Terminal half-life (T1/2)

    Time frame: Cycle 1 Day 1 to day of the last dose of HFB301001 (each cycle is 28 days)

  9. Serum concentration for measurement of anti-HFB301001 antibodies

    Time frame: Cycle 1 Day 1 to day of the last dose of HFB301001 (each cycle is 28 days)

  10. To assess the pharmacodynamic (PD) effects of HFB301001 in the blood and in the tumor

    Percent change in immunologic changes to immune cells in the blood and tumor

    Time frame: Cycle 1 Day 1 to Cycle 3 Day 2 (each cycle is 28 days)

07

Study locations

10 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • NEXT Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
08

References and documents

Publications

  • Zhao J, Zhang D, Lu YY, Jin R, Li F, Zhang Z, Ni W, Gong N, Wang Y, Yin Z, Du Y, Ma W, Wang X, Zu L, Liu S, Yang K, Bai Y, Gan J, Adrian F, Hong Z, Zhang S, Chang Y, Wang Z, Jin X, Zhong J, Ge K, Peng S, Ding D, Zheng W, Xu S, Wang W, Schweizer L, Zhang H. HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering. J Immunother Cancer. 2026 Mar 30;14(3):e014185. doi: 10.1136/jitc-2025-014185. PubMed 41912269 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2024, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 8, 2022
StartActual
Apr 20, 2022
Primary completionActual
May 30, 2024
CompletionActual
May 30, 2024
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05229601
Lead sponsor
HiFiBiO Therapeutics
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Apr 20, 2022
Primary completion
May 30, 2024
Completion
May 30, 2024
Last update
Oct 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion